Eli Lilly agrees to buy cancer biotech Kelonia for up to $7 billion
Kelonia’s lead drug aims to treat patients who have a form of blood cancer called multiple myeloma and aren’t responding to treatment.
- Eli Lilly to buy Boston biotech Kelonia for $3.25 billion Boston Globe —
- Eli Lilly Announces $7 Billion Deal. What It Means for the Stock. Barrons —
- Eli Lilly Stock Falls as It Closes in on a $2 Billion Deal. Here’s Why. Barrons —
- Eli Lilly agrees to acquire cancer drug maker Kelonia in deal worth up to $7 billion CNBC —